MCID: NRM008
MIFTS: 34

Neuromyelitis Optica Spectrum Disorder

Categories: Eye diseases, Immune diseases, Neuronal diseases, Rare diseases

Aliases & Classifications for Neuromyelitis Optica Spectrum Disorder

MalaCards integrated aliases for Neuromyelitis Optica Spectrum Disorder:

Name: Neuromyelitis Optica Spectrum Disorder 54
Neuromyelitis Optica 74
Nmosd 54

Classifications:



External Ids:

UMLS 74 C0027873

Summaries for Neuromyelitis Optica Spectrum Disorder

MalaCards based summary : Neuromyelitis Optica Spectrum Disorder, also known as neuromyelitis optica, is related to neuromyelitis optica and multiple sclerosis. An important gene associated with Neuromyelitis Optica Spectrum Disorder is AQP4 (Aquaporin 4). The drugs Prednisone and Mycophenolic acid have been mentioned in the context of this disorder. Affiliated tissues include brain, t cells and spinal cord.

Related Diseases for Neuromyelitis Optica Spectrum Disorder

Diseases in the Neuromyelitis Optica family:

Neuromyelitis Optica Spectrum Disorder

Diseases related to Neuromyelitis Optica Spectrum Disorder via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 110)
# Related Disease Score Top Affiliating Genes
1 neuromyelitis optica 11.5
2 multiple sclerosis 10.9
3 sjogren syndrome 10.7
4 optic neuritis 10.7
5 neuritis 10.7
6 myelitis 10.7
7 transverse myelitis 10.6
8 encephalitis 10.5
9 autoimmune disease 10.4
10 autoimmune disease 1 10.4
11 alpha/beta t-cell lymphopenia with gamma/delta t-cell expansion, severe cytomegalovirus infection, and autoimmunity 10.4
12 depression 10.4
13 systemic lupus erythematosus 10.4
14 myasthenia gravis 10.4
15 adenocarcinoma 10.4
16 lupus erythematosus 10.4
17 myasthenia gravis congenital 10.4
18 anxiety 10.3
19 cytokine deficiency 10.3
20 encephalopathy 10.3
21 scleroderma, familial progressive 10.2
22 lung cancer susceptibility 3 10.2
23 hepatitis 10.2
24 hepatitis b 10.2
25 lymphoma 10.2
26 apraxia 10.2
27 leukodystrophy 10.2
28 internuclear ophthalmoplegia 10.2
29 acute disseminated encephalomyelitis 10.2
30 influenza 10.2
31 spondyloarthropathy 1 10.1
32 esophageal cancer 10.1
33 split-hand/foot malformation 1 10.1
34 spondylosis, cervical 10.1
35 anemia, autoimmune hemolytic 10.1
36 galactorrhea 10.1
37 moyamoya disease 1 10.1
38 biotinidase deficiency 10.1
39 ataxia and polyneuropathy, adult-onset 10.1
40 yemenite deaf-blind hypopigmentation syndrome 10.1
41 salla disease 10.1
42 mycobacterium tuberculosis 1 10.1
43 dengue virus 10.1
44 membranous nephropathy 10.1
45 ataxia, combined cerebellar and peripheral, with hearing loss and diabetes mellitus 10.1
46 arteriovenous fistula 10.1
47 brain injury 10.1
48 bronchiolitis obliterans 10.1
49 follicular lymphoma 10.1
50 hemolytic anemia 10.1

Graphical network of the top 20 diseases related to Neuromyelitis Optica Spectrum Disorder:



Diseases related to Neuromyelitis Optica Spectrum Disorder

Symptoms & Phenotypes for Neuromyelitis Optica Spectrum Disorder

Drugs & Therapeutics for Neuromyelitis Optica Spectrum Disorder

Drugs for Neuromyelitis Optica Spectrum Disorder (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 86)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Prednisone Approved, Vet_approved Phase 4 53-03-2 5865
2
Mycophenolic acid Approved Phase 4 24280-93-1 446541
3
Mitoxantrone Approved, Investigational Phase 4 65271-80-9 4212
4 Hormones, Hormone Substitutes, and Hormone Antagonists Phase 4,Phase 3,Phase 2,Phase 1
5 Anti-Inflammatory Agents Phase 4,Phase 3,Phase 2,Phase 1
6 Anti-Infective Agents Phase 4
7 Antibiotics, Antitubercular Phase 4
8 Antitubercular Agents Phase 4
9 Antineoplastic Agents, Hormonal Phase 4,Phase 2,Phase 3,Phase 1
10 glucocorticoids Phase 4,Phase 3,Phase 2,Phase 1
11 Anti-Bacterial Agents Phase 4
12 Hormones Phase 4,Phase 3,Phase 2,Phase 1
13 Hormone Antagonists Phase 4,Phase 3,Phase 2,Phase 1
14 Peripheral Nervous System Agents Phase 4,Phase 3,Phase 2,Phase 1
15 Topoisomerase Inhibitors Phase 4
16 Analgesics Phase 4
17
Prednisolone phosphate Approved, Vet_approved Phase 3,Phase 2,Phase 1 302-25-0
18
Methylprednisolone hemisuccinate Approved Phase 3,Phase 2,Phase 1 2921-57-5
19
Prednisolone Approved, Vet_approved Phase 3,Phase 2,Phase 1 50-24-8 5755
20
Methylprednisolone Approved, Vet_approved Phase 3,Phase 2,Phase 1 83-43-2 6741
21
Azathioprine Approved Phase 2, Phase 3,Phase 3 446-86-6 2265
22
rituximab Approved Phase 2, Phase 3,Phase 3,Phase 1 174722-31-7 10201696
23
Ifosfamide Approved Phase 2, Phase 3,Phase 1 3778-73-2 3690
24
Mesna Approved, Investigational Phase 2, Phase 3,Phase 1 3375-50-6 598
25
Cyclophosphamide Approved, Investigational Phase 2, Phase 3,Phase 1 50-18-0, 6055-19-2 2907
26
Sargramostim Approved, Investigational Phase 2, Phase 3 123774-72-1, 83869-56-1
27
Lenograstim Approved, Investigational Phase 2, Phase 3,Phase 1 135968-09-1
28
Prednisolone hemisuccinate Experimental Phase 3,Phase 2,Phase 1 2920-86-7
29 Gastrointestinal Agents Phase 3,Phase 2,Phase 1
30 Protective Agents Phase 3,Phase 2,Phase 1
31 Antiemetics Phase 3,Phase 2,Phase 1
32 Methylprednisolone Acetate Phase 3,Phase 2,Phase 1
33 Prednisolone acetate Phase 3,Phase 2,Phase 1
34 Autonomic Agents Phase 3,Phase 2,Phase 1
35 Neuroprotective Agents Phase 3,Phase 2,Phase 1
36 Immunologic Factors Phase 2, Phase 3,Phase 3,Phase 1
37 Antibodies Phase 3,Phase 2,Phase 1,Not Applicable
38 Immunoglobulins Phase 3,Phase 2,Phase 1,Not Applicable
39 Immunosuppressive Agents Phase 2, Phase 3,Phase 3,Phase 1
40 Antimetabolites, Antineoplastic Phase 2, Phase 3,Phase 3
41 Antirheumatic Agents Phase 2, Phase 3,Phase 3,Phase 1
42 Antimetabolites Phase 2, Phase 3,Phase 3
43 Antineoplastic Agents, Immunological Phase 2, Phase 3,Phase 3,Phase 1
44 Immunoglobulins, Intravenous Phase 2, Phase 3,Phase 3
45 Rho(D) Immune Globulin Phase 2, Phase 3,Phase 3
46 gamma-Globulins Phase 2, Phase 3,Phase 3
47 Immunoglobulin G Phase 3,Phase 2
48 Antineoplastic Agents, Alkylating Phase 2, Phase 3,Phase 1
49 polysaccharide-K Phase 2, Phase 3,Phase 1
50
Isophosphamide mustard Phase 2, Phase 3,Phase 1 0

Interventional clinical trials:

(show top 50) (show all 53)
# Name Status NCT ID Phase Drugs
1 Mycophenolate Mofetil Treatment With Neuromyelitis Optica Spectrum Disorders in Chinese Patients Unknown status NCT02809079 Phase 4 Mycophenolate mofetil;Prednisone
2 Efficacy and Safety of Mitoxantrone in Patients With Refractory Neuromyelitis Optica and Spectrum Disorders Unknown status NCT02021825 Phase 4 Mitoxantrone
3 A Pilot Study of Mitoxantrone for the Treatment of Recurrent Neuromyelitis Optica (Devic’s Disease) Completed NCT00304291 Phase 4 Mitoxantrone
4 Phase III Randomized, Double-Blind, Sham-Controlled Study of Plasma Exchange for Acute Severe Attacks of Inflammatory Demyelinating Disease Refractory to Intravenous Methylprednisolone Unknown status NCT00004645 Phase 3
5 Comparison of Clinical Effects of Azathioprine and Rituximab NMO-SD Patients Completed NCT03002038 Phase 2, Phase 3 Azathioprine;Rituximab
6 A Double Blind Trial To Evaluate The Safety And Efficacy Of Eculizumab In Relapsing NMO Patients (PREVENT Study) Completed NCT01892345 Phase 3 Eculizumab
7 A Phase III Study of TACI-antibody Fusion Protein Injection (RC18) in Subjects With Neuromyelitis Optica Spectrum Disorders Recruiting NCT03330418 Phase 3
8 Autologous Transplant To End NMO Spectrum Disorder Recruiting NCT03829566 Phase 2, Phase 3 Rituximab;Cyclophosphamide;Mesna;rATG;Methylprednisolone;G-CSF
9 Tocilizumab vs Azathioprine in Neuromyelitis Optica Spectrum Disorders Active, not recruiting NCT03350633 Phase 2, Phase 3 Tocilizumab Injection;Azathioprine
10 A Double-masked, Placebo-controlled Study With Open Label Period to Evaluate MEDI-551 in Neuromyelitis Optica and Neuromyelitis Optica Spectrum Disorders Active, not recruiting NCT02200770 Phase 2, Phase 3
11 An Open Label Extension Trial of Eculizumab in Relapsing NMO Patients Active, not recruiting NCT02003144 Phase 3
12 Efficacy and Safety Study as Add-on Therapy of Satralizumab (SA237) to Treat NMO and NMOSD Active, not recruiting NCT02028884 Phase 3 satralizumab (SA237);Placebo
13 Efficacy and Safety Study as Monotherapy of Satralizumab (SA237) to Treat NMO and NMOSD Active, not recruiting NCT02073279 Phase 3 satralizumab (SA237);Placebo
14 A Multicentre randomiSed Controlled TRial of IntraVEnous Immunoglobulin Versus Standard Therapy for Transverse Myelitis Terminated NCT02398994 Phase 3 Intravenous Methylprednisolone;Intravenous Immunoglobulin
15 Safety and Efficacy of Umbilical Cord Mesenchymal Stem Cell Therapy for Patients With Progressive Multiple Sclerosis and Neuromyelitis Optica Unknown status NCT01364246 Phase 1, Phase 2
16 Phase II Clinical Trial of NPB-01 in Patients With Anti-aquaporin 4 Antibody Positive Neuromyelitis Optica Spectrum Disorder Not Provided Adequate Effect of Therapy to Steroids Plus Therapy. Completed NCT01845584 Phase 2 NPB-01
17 Efficacy and Safety of Bortezomib as add-on Treatment in Relapsing Neuromyelitis Optica Spectrum Disorder Completed NCT02893111 Phase 2 Bortezomib
18 Neuromyelitis Optica (NMO) & Cetirizine Completed NCT02865018 Phase 1, Phase 2 cetirizine
19 Autologous Mesenchymal Stem Cells for the Treatment of Neuromyelitis Optica Spectrum Disorders Completed NCT02249676 Phase 2
20 An Open Label Study of the Effects of Eculizumab in Neuromyelitis Optica Completed NCT00904826 Phase 1, Phase 2 Eculizumab
21 A Longitudinal Study of ACTEMRA® (Tocilizumab) as Monotherapy in Highly Active NMOSD Completed NCT03062579 Phase 1, Phase 2 Tocilizumab
22 Safety and Efficacy of Sustained Release Dalfampridine in Transverse Myelitis (Re-Launch) Completed NCT02166346 Phase 2 Dalfampridine;Placebo
23 Hematopoietic Stem Cell Transplant in Devic's Disease Active, not recruiting NCT00787722 Phase 1, Phase 2 Cyclophosphamide;G-CSF;rATG;Mesna;Rituximab;Methylprednisolone
24 Autologous Hematopoietic Stem Cell Transplant in Neuromyelitis Optica Terminated NCT01339455 Phase 1, Phase 2
25 C1-esterase Inhibitor (Cinryze) for Acute Treatment of Neuromyelitis Optica Exacerbation Completed NCT01759602 Phase 1 C1-esterase inhibitor (Cinryze)
26 Efficacy of Bevacizumab (Avastin) in Treatment of Acute NMO Exacerbations Completed NCT01777412 Phase 1 Bevacizumab
27 Safety and Tolerability of Rituximab in Neuromyelitis Optica Completed NCT00501748 Phase 1 Rituximab
28 Central Pain Study for ABX-1431 Completed NCT03138421 Phase 1 ABX-1431 HCl;Placebo
29 Treatment of Multiple Sclerosis and Neuromyelitis Optica With Regulatory Dendritic Cell: Clinical Trial Phase 1 B Recruiting NCT02283671 Phase 1
30 Ublituximab for Acute Neuromyelitis Optica (NMO) Relapses Active, not recruiting NCT02276963 Phase 1 Ublituximab
31 Treatment of Relapsed and/or Refractory AQP4-IgG Seropositive NMOSD by Tandem CAR T Cells Targeting CD19 and CD20 Not yet recruiting NCT03605238 Phase 1
32 Pilot Study of alpha1-antitrypsin to Treat Neuromyelitis Optica Relapses Withdrawn NCT02087813 Phase 1 Alpha1-antitrypsin;methylprednisolone
33 Evaluation of Neural Loss in Multiple Sclerosis and Neuromyelitis Optica Using High Resolution Oct Unknown status NCT01024985
34 The Correlation Between AQP-4 Ab and the Visual Function of Patients With Demyelinating ON at Onset Unknown status NCT02886377
35 Quantitation of McArdle's Sign and Evaluation of Specificity for Multiple Sclerosis Completed NCT03122873
36 Pathologic-MRI Findings in Atypical IIDD Completed NCT03121105
37 Multimodel Magnetic Resonance Imaging (MRI)of Multiple Sclerosis and Neuromyelitis Optica Spectrum Disorders Recruiting NCT02836327
38 Pediatric NMOSD Observational Study Recruiting NCT03766347
39 The French Cohort and Biobank of Devic's Neuromyelitis Optica and Related Neurological Disorders (NMOSD) (NOMADMUS) Recruiting NCT02850705
40 The Longitudinal CONQUER Study of Rare Neuroimmunologic Disorders Recruiting NCT01623076
41 The French Multiple Sclerosis Registry Recruiting NCT02889965
42 Analysis of the Distribution of Regulatory B Cells in Blood of Multiple Sclerosis Patients Recruiting NCT02789670
43 Stem Cell Ophthalmology Treatment Study II Recruiting NCT03011541 Not Applicable
44 Maintenance Plasma Exchange for Neuromyelitis Optica Active, not recruiting NCT01500681
45 Scrambler Trial for Pain in NMOSD Active, not recruiting NCT03452176 Not Applicable
46 Biobank For MS And Other Demyelinating Diseases Active, not recruiting NCT00445367
47 Optical Coherence Tomography and Optic Neuritis (OCTON) Active, not recruiting NCT02573792
48 Clinic Registry Study of Optic Neuromyelitis Spectrum Disease in China Enrolling by invitation NCT03514030
49 Stem Cell Ophthalmology Treatment Study Enrolling by invitation NCT01920867 Not Applicable
50 Clinical Patterns of Neuromyelitis Optica Spectrum Disorders in Assiut University Hospital Not yet recruiting NCT03819413

Search NIH Clinical Center for Neuromyelitis Optica Spectrum Disorder

Genetic Tests for Neuromyelitis Optica Spectrum Disorder

Anatomical Context for Neuromyelitis Optica Spectrum Disorder

MalaCards organs/tissues related to Neuromyelitis Optica Spectrum Disorder:

42
Brain, T Cells, Spinal Cord, B Cells, Testes, Neutrophil, Eye

Publications for Neuromyelitis Optica Spectrum Disorder

Articles related to Neuromyelitis Optica Spectrum Disorder:

(show top 50) (show all 2036)
# Title Authors Year
1
Brain MRI Findings in Pediatric-Onset Neuromyelitis Optica Spectrum Disorder: Challenges in Differentiation from Acute Disseminated Encephalomyelitis. ( 30846436 )
2019
2
Callosal lesions on magnetic resonance imaging with multiple sclerosis, neuromyelitis optica spectrum disorder and acute disseminated encephalomyelitis. ( 31030018 )
2019
3
Clinical Approach to Pediatric Transverse Myelitis, Neuromyelitis Optica Spectrum Disorder and Acute Flaccid Myelitis. ( 31109018 )
2019
4
Neuromyelitis optica spectrum disorder with lung adenocarcinoma and intraductal papillary mucinous neoplasm. ( 31060025 )
2019
5
Neuromyelitis optica spectrum disorder and adenocarcinoma of ovary: a novel association. ( 31023729 )
2019
6
Case report: an area postrema syndrome revealing a neuromyelitis optica spectrum disorder associated with central nervous system tuberculosis in a young Togolese (black African) woman. ( 30971218 )
2019
7
Neuromyelitis optica: an elusive cause of dysphagia. ( 30642856 )
2019
8
Hemorrhagic encephalitis in a patient with neuromyelitis optica: A case report. ( 30985265 )
2019
9
Limbic encephalitis-like presentation in neuromyelitis optica spectrum disorder: a case report. ( 30835052 )
2019
10
Hypertrophic olivary degeneration mimics relapse in neuromyelitis optica spectrum disorder. ( 30745445 )
2019
11
A case of neuromyelitis optica spectrum disorder following seasonal influenza vaccination. ( 30769255 )
2019
12
Coexistence of Neuromyelitis Optica and Amyotrophic Lateral Sclerosis: A Case Report. ( 30671163 )
2019
13
A Little-Known Brain Imaging Feature in Neuromyelitis Optica Spectrum Disorder: A Leukodystrophy-Like Pattern. ( 30877700 )
2019
14
Neuromyelitis optica spectrum disorder occurred after interferon alpha therapy in malignant melanoma. ( 31030016 )
2019
15
Corrigendum to "Foxp3+ regulatory T cells expression in Neuromyelitis optica spectrum disorders" [Multiple Sclerosis and Related Disorders 30 (2019) 114-118]. ( 30987752 )
2019
16
Immune tolerance in multiple sclerosis and neuromyelitis optica with peptide-loaded tolerogenic dendritic cells in a phase 1b trial. ( 30962374 )
2019
17
The Role of B Cells and Antibodies in Multiple Sclerosis, Neuromyelitis Optica, and Related Disorders. ( 30800132 )
2019
18
Can Visual Testing Be Used to Distinguish Neuromyelitis Optica and Multiple Sclerosis? ( 30803517 )
2019
19
Comparison of Ocular Motor Findings Between Neuromyelitis Optica Spectrum Disorder and Multiple Sclerosis Involving the Brainstem and Cerebellum. ( 30827013 )
2019
20
Association of Optic Neuritis with Neuromyelitis Optica Spectrum Disorder and Multiple Sclerosis in Korea. ( 30746915 )
2019
21
Radiomics in multiple sclerosis and neuromyelitis optica spectrum disorder. ( 30770971 )
2019
22
Immunoadsorption or plasma exchange in steroid-refractory multiple sclerosis and neuromyelitis optica. ( 30698295 )
2019
23
Spinal cord involvement in multiple sclerosis and neuromyelitis optica spectrum disorders. ( 30663608 )
2019
24
Quantitative radiomic biomarkers for discrimination between neuromyelitis optica spectrum disorder and multiple sclerosis. ( 30408268 )
2019
25
Peripheral CD19+ B-cell counts and infusion intervals as a surrogate for long-term B-cell depleting therapy in multiple sclerosis and neuromyelitis optica/neuromyelitis optica spectrum disorders. ( 30377816 )
2019
26
Differing Structural and Functional Patterns of Optic Nerve Damage in Multiple Sclerosis and Neuromyelitis Optica Spectrum Disorder. ( 30060979 )
2019
27
Plasma exchange: an effective add-on treatment of optic neuritis in neuromyelitis optica spectrum disorders. ( 30825049 )
2019
28
Sequential Optic Neuritis: A Neuromyelitis Optica Spectrum Disorder. ( 30925966 )
2019
29
The association between dietary sugar intake and neuromyelitis optica spectrum disorder: A case-control study. ( 30978652 )
2019
30
Neuromyelitis optica spectrum disorder in a tertiary hospital in the Philippines: a case series. ( 30981191 )
2019
31
Aquaporin 4 distribution in the brain and its relevance for the radiological appearance of neuromyelitis optica spectrum disease. ( 30981824 )
2019
32
Expression of OX40 Gene and its Serum Levels in Neuromyelitis Optica Patients. ( 30995203 )
2019
33
Cerebral cortex impairment in neuromyelitis optica spectrum disorder: A case report and literature review. ( 31005027 )
2019
34
Efficacy and tolerability of mitoxantrone for neuromyelitis optica spectrum disorder: A systematic review. ( 31005713 )
2019
35
Clinical Characteristics of Patients With Neuromyelitis Optica Spectrum Disorders With Early Onset. ( 31012355 )
2019
36
A case where selective plasma exchange for neuromyelitis optica was effective. ( 31025803 )
2019
37
Role of Glutamatergic Excitotoxicity in Neuromyelitis Optica Spectrum Disorders. ( 31031597 )
2019
38
Neuromyelitis optica spectrum disorder with area postrema syndrome. ( 31041136 )
2019
39
Eculizumab in Aquaporin-4-Positive Neuromyelitis Optica Spectrum Disorder. ( 31050279 )
2019
40
Early B cell tolerance defects in neuromyelitis optica favour anti-AQP4 autoantibody production. ( 31056665 )
2019
41
Comparison of sleep complaints and quality of life between patients with neuromyelitis optica spectrum disorder (NMOSD) and healthy controls. ( 31063950 )
2019
42
Myelin Oligodendrocyte Glycoprotein Antibody-Associated Neuromyelitis Optica Spectrum Disorder in a 6-Year-Old Boy. ( 31064015 )
2019
43
Neuromyelitis optica spectrum disorder in three generations of a Chinese family. ( 31075495 )
2019
44
Functional brain connectivity abnormalities and cognitive deficits in neuromyelitis optica spectrum disorder. ( 31079538 )
2019
45
HLA-alleles class I and II associated with genetic susceptibility to neuromyelitis optica in Brazilian patients. ( 31090804 )
2019
46
A comparison between spinal cord infarction and neuromyelitis optica spectrum disorders: Clinical and MRI studies. ( 31092838 )
2019
47
Review of Treatment for Central Spinal Neuropathic Pain and Its Effect on Quality of Life: Implications for Neuromyelitis Optica Spectrum Disorder. ( 31103517 )
2019
48
Resolution of inflammation in neuromyelitis optica spectrum disorders. ( 30300851 )
2019
49
Altered neurovascular coupling in neuromyelitis optica. ( 30315685 )
2019
50
MRI findings in pediatric neuromyelitis optica spectrum disorder with MOG antibody: Four cases and review of the literature. ( 30447856 )
2019

Variations for Neuromyelitis Optica Spectrum Disorder

Expression for Neuromyelitis Optica Spectrum Disorder

Search GEO for disease gene expression data for Neuromyelitis Optica Spectrum Disorder.

Pathways for Neuromyelitis Optica Spectrum Disorder

GO Terms for Neuromyelitis Optica Spectrum Disorder

Sources for Neuromyelitis Optica Spectrum Disorder

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
20 FMA
29 GO
30 GTR
31 HGMD
32 HMDB
33 HPO
34 ICD10
35 ICD10 via Orphanet
36 ICD9CM
37 IUPHAR
38 KEGG
39 LifeMap
41 LOVD
43 MedGen
45 MeSH
46 MESH via Orphanet
47 MGI
50 NCI
51 NCIt
52 NDF-RT
55 NINDS
56 Novoseek
58 OMIM
59 OMIM via Orphanet
63 PubMed
65 QIAGEN
70 SNOMED-CT via HPO
71 SNOMED-CT via Orphanet
72 TGDB
73 Tocris
74 UMLS
75 UMLS via Orphanet
Content
Loading form....